Kratom's Regulatory Patchwork: What Supplement Brands Need to Test Before Selling Across State Lines

Sometime in 2016, the DEA placed kratom on its emergency scheduling list as a Schedule I controlled substance. The proposed rule drew an extraordinary public response — more than 23,000 written comments, a congressional letter signed by 51 members of the House and Senate, and sharp criticism from researchers who argued the evidence didn’t support emergency classification. The agency withdrew the notice four months later. That was nearly a decade ago. Since then, kratom regulation hasn’t simplified. It’s just moved to the states.

Today, nine states have enacted some version of the Kratom Consumer Protection Act (KCPA). Six states have banned the substance outright. Federal regulatory status remains ambiguous: FDA has issued import alerts and warning letters to manufacturers, but has declined to formally schedule kratom under the Controlled Substances Act or to establish binding quality standards under DSHEA. The result for supplement brands is a compliance challenge with no central authority and no uniform testing standard. If you’re selling kratom products nationally, you’re navigating a patchwork — and the testing obligations within that patchwork are real.

The State-Level Regulatory Landscape Has Real Teeth Now

Six states currently prohibit kratom products entirely: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. These aren’t gray areas. Selling kratom-containing products in these markets creates direct legal liability, and no testing panel changes that calculus.

The more complex territory is the KCPA states. As of 2026, Utah, Georgia, Arizona, Nevada, Colorado, Oregon, Virginia, Oklahoma, and Texas have all enacted KCPA-based legislation — though the specific requirements vary by state. The law’s core provisions are broadly consistent: age restrictions (18+ or 21+ depending on jurisdiction), a prohibition on synthetic kratom alkaloids, a requirement that products carry alkaloid content labeling, and some form of manufacturer registration or testing requirement. But the details diverge in ways that matter analytically.

Utah’s KCPA caps 7-hydroxymitragynine (7-OH-mitragynine) at 2% of total alkaloid content by weight. Colorado’s version cuts that limit in half, to 1% of total alkaloids. Virginia prohibits any synthetic alkaloid derivatives — which requires a testing panel capable of distinguishing naturally occurring alkaloids from synthetic forms. These differences are easy to overlook, and significant enough to result in product seizures and retailer de-listing if your certificate of analysis (COA) doesn’t address the right parameters for each market.

FDA’s posture adds another layer of uncertainty. The agency’s Import Alert 54-15, updated in 2019, allows for the detention of kratom products at the U.S. border without physical examination. That alert has been expanded over time and currently covers a broad range of kratom-containing products. Domestically manufactured products face a different but equally unpredictable environment: FDA has issued warning letters to kratom brands citing adulteration claims, improper disease claims in labeling, and GMP failures. None of this constitutes formal drug scheduling — but enforcement actions do create liability that intersects with any state-level compliance gap you haven’t closed.

What the KCPA Actually Requires From Your Testing Program

The Kratom Consumer Protection Act is not prescriptive about analytical methods. It specifies outcomes — what must appear on a label, what concentrations are prohibited — not the procedures used to generate those numbers. The burden of choosing appropriate testing methodology falls entirely on the manufacturer or brand.

In practice, a KCPA-compliant testing program needs to address three categories.

Alkaloid quantification. This is the analytical core. You need to know, at minimum, the mitragynine concentration and the 7-OH-mitragynine concentration in your finished product. Mitragynine is the primary alkaloid in Mitragyna speciosa, typically comprising 1–2% of dried leaf by weight. In extract products, concentrations can reach 30 mg/g or higher — a range that makes generic “alkaloid content” labeling essentially meaningless without specific method-level quantification.

Liquid chromatography with tandem mass spectrometry (LC-MS/MS) is the appropriate analytical approach. It can simultaneously quantify mitragynine, 7-OH-mitragynine, speciociliatine, paynantheine, and other minor alkaloids with the selectivity that KCPA-compliant labeling actually requires. HPLC-UV methods exist but lack the specificity to reliably distinguish kratom alkaloids from co-eluting matrix compounds, particularly in high-concentration extract products. If your COA is generated from HPLC-UV data, it may not withstand regulatory scrutiny in states with strict alkaloid limits.

Heavy metal testing. Any botanical product sold to consumers carries elemental impurity risk, and kratom is no exception. Lead and cadmium are the primary concerns — Mitragyna speciosa bioaccumulates minerals from its growing environment, and sourcing practices vary significantly across Southeast Asian suppliers. USP <232> establishes oral daily exposure limits for elemental impurities: 5 µg/day for lead, 2 µg/day for cadmium. Most KCPA states either reference these USP limits or defer to FDA guidance on elemental impurities for dietary supplements. ICP-MS analysis with acid digestion is the standard approach. A single supplier COA on raw material is not a substitute for finished product lot testing — elemental concentrations can shift with blending, encapsulation, and formulation changes.

Microbial testing. Kratom powder carries meaningful microbial risk. The plant is dried and processed in tropical environments where temperature and humidity create favorable conditions for mold, bacterial proliferation, and Salmonella. USP <61> and <62> provide the standard acceptance criteria: total aerobic microbial count (TAMC), total yeast and mold count (TYMC), and absence of specified organisms including Salmonella spp. and Escherichia coli. KCPA states don’t universally mandate microbial testing by statute, but any product positioned as a dietary supplement should meet USP acceptance criteria as a baseline — and any retailer doing their own compliance diligence will expect to see this data on your COA.

Why Multi-State Compliance Means Testing to the Strictest Limit

Here’s the practical problem: if you’re manufacturing one kratom product and distributing it in multiple KCPA states, you can’t run a different testing panel for each market. You need to build a program that satisfies the most stringent requirements across every state in your distribution footprint, and document accordingly.

That means your COA needs to show 7-OH-mitragynine at a concentration that clears Colorado’s 1% of total alkaloid limit — not just Utah’s 2% threshold. It means your alkaloid quantification method needs to be precise enough to report at concentrations where these state limits become meaningful. At Colorado’s 1% cap applied to a product with, say, 15 mg/g total mitragynine, you’re looking for 7-OH-mitragynine at or below approximately 0.15 mg/g. That demands a validated method with a limit of quantitation well below that concentration — and documented proof that your method actually achieves it.

And this is where ISO 17025 accreditation matters in a practical sense. KCPA regulations don’t universally mandate testing by an accredited laboratory. But they require testing documentation that regulators and downstream retailers can rely on. An ISO 17025 accredited lab operates under a formally validated quality management system, with documented method validations, measurement uncertainty estimates, and participation in external proficiency testing programs. When a state enforcement office or a national retailer’s compliance team reviews your COA, accreditation is the shortest path to credibility. Results from an unaccredited source — even technically sound ones — carry the kind of audit risk that accredited results don’t.

Where Labs Actually See Failures in Kratom Samples

A few patterns show up consistently in kratom testing that brands should understand before finalizing their compliance program.

Extract products frequently fail to match label claims on mitragynine content. Extract ratios like “10x” or “50x” have no standardized definition — they’re marketing constructs, not analytical statements. We’ve seen products labeled as high-potency extracts that assay at concentrations consistent with dried leaf. We’ve also seen the opposite: products positioned as moderate-strength extracts with mitragynine concentrations significantly above consumer expectations. Either scenario creates regulatory exposure and potential for harm.

Microbial contamination in raw powder is more common than most brands anticipate. Salmonella is the organism of greatest concern — it shows up in dried botanical materials more often than in most other supplement ingredient categories. A one-time test at initial production isn’t adequate. Finished product testing on every manufactured lot is the defensible standard, and the cost of that testing is small relative to the cost of a voluntary recall or retailer suspension.

Heavy metal variability across sourcing lots is real, and it’s driven primarily by soil and regional origin. Kratom from different growing areas in Indonesia, Malaysia, and Thailand can differ materially in cadmium and lead uptake depending on local soil chemistry and agricultural practices. Brands relying on a single historical supplier COA are accumulating risk that lot-level finished product testing would identify and contain.

Building a Testing Program Before the Patchwork Tightens Further

The kratom regulatory landscape will keep evolving. More states are actively considering KCPA legislation. The American Kratom Association has been lobbying for federal KCPA adoption — legislation that would create a uniform national standard and would actually simplify compliance compared to today’s state-by-state environment. But until that happens, the burden falls on individual brands to know which markets they serve, what those markets require, and whether their testing documentation actually demonstrates compliance.

The starting point is straightforward: run a full alkaloid profile by LC-MS/MS, ICP-MS heavy metal testing, and a USP <61>/<62> microbial panel on every production lot. Work with a lab whose kratom alkaloid methods are validated and can report 7-OH-mitragynine at concentrations meaningful to KCPA limits. Verify that your COA identifies the specific alkaloids the regulations address — not just a total alkaloid figure, which satisfies no state’s requirements.

If you’re distributing across multiple KCPA states, map the requirements of each and design your testing program to satisfy the most stringent. Document that mapping. When a retailer or state regulator asks why your testing program is structured the way it is, you want an answer that’s already written down.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA Regulatory Strategy for Ambiguously Classified Botanical Products — Aurora TIC advises brands navigating gray-area FDA classifications, including botanical ingredients without established drug or supplement status.
• Supplier Qualification and Raw Material COA Verification for Botanicals — Ayah Labs supports brands in verifying raw material quality claims from international botanical suppliers before production begins.